Jade Biosciences Appoints Mark Eisner to Board of Directors
Jade Biosciences, Inc. announced the appointment of Mark Eisner, M.D., M.P.H., to its Board of Directors, effective June 25, 2026. Dr. Eisner brings over 25 years of leadership in clinical development and immunology, having previously served as Executive Vice President and Chief Medical Officer at Vir Biotechnology, and Chief Medical Officer at Sonoma Biotherapeutics and FibroGen. He also held a senior leadership role at Genentech/Roche, overseeing multinational development programs. The company's CEO, Tom Frohlich, emphasized Dr. Eisner's valuable experience in advancing innovative therapies from early clinical development to global commercialization, which will support Jade's pipeline of antibody-based therapies for autoimmune diseases.
Key Highlights
- Jade Biosciences appointed Mark Eisner, M.D., M.P.H., to its Board of Directors, effective June 25, 2026.
- Dr. Eisner has over 25 years of leadership experience in clinical development and immunology.
- He previously served as Executive Vice President and Chief Medical Officer at Vir Biotechnology.
- Dr. Eisner also held Chief Medical Officer roles at Sonoma Biotherapeutics and FibroGen.
- He spent nearly 11 years at Genentech/Roche, including as Senior Vice President and Global Head of Product Development for Immunology, Infectious Disease, and Ophthalmology.
- CEO Tom Frohlich highlighted Dr. Eisner's track record in guiding therapies from early clinical development through regulatory approval and commercialization.
Price Impact
More from JBIO